Close
Smartlab Europe
Inizio Ignite

Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...
- Advertisement -
Smart Lab Europe

Global contract development and manufacturing organisation (CDMO) Recipharm, has announced the appointment of Joaquim Mascaro as Chief Financial Officer.

Joaquim has worked for a range of organisations in the pharma, biotech and healthcare industries, across the US, Asia and Latin America. His experience in building and developing strong teams will be essential in supporting the organisation through its next phase of growth.

Marc Funk, CEO Recipharm said: “I am delighted to welcome Joaquim to the Recipharm team as we continue to drive our business forward. Joaquim’s impressive credentials and expertise will be a real asset to the senior leadership team and to the business”.

Commenting on his appointment, Joaquim said: “Recipharm’s reputation and service offering in the industry is second to none. I am thrilled to be working for a leading top five CDMO on the quest for continuous growth”.

Joaquim joins on 3 April 2023 and replaces Michael Tyroller, who was interim CFO.

Smart Lab Europe

Latest stories

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...

FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC

Johnson & Johnson (J&J) has obtained approval from the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »